Background Cardiorespiratory failure is the leading cause of death in Duchenne muscular dystrophy. Based on preclinical and phase 2 evidence, we assessed the effi cacy and safety of idebenone in young patients with Duchenne muscular dystrophy who were not taking concomitant glucocorticoids.
Introduction
Duchenne muscular dystrophy is the most common and devastating type of muscular dystrophy. 1 Progressive weakness of respiratory muscles leads to restrictive pulmonary disease that evolves into respiratory compli cations and early morbidity and mortality. [2] [3] [4] [5] [6] [7] Glucocorticoids are the only medications that can slow the decline in muscle strength and function and delay the onset and progression of respiratory dysfunction. [8] [9] [10] However, not all patients with Duchenne muscular dystrophy respond to steroids to the same extent and the well known side-eff ects of steroids restrict their clinical use, particularly in non-ambulatory patients in the later stage of the disease. In a natural history study, 42% of patients with Duchenne muscular dystrophy aged 10 years and older had never used glucocorticoids or discontinued their use because of side-eff ects and tolerability limitations. 9 Consequently, for many patients with Duchenne muscular dystrophy there are no pharma cological treatment options at about the age when patients become non-ambulatory and the decline in their respiratory function becomes clinically relevant.
The short-chain benzoquinone idebenone is a potent antioxidant and inhibitor of lipid peroxidation that is capable of stimulating mitochondrial electron fl ux and cellular energy production.
11, 12 The results of a placebo-controlled study in the mdx mouse showed signifi cant cardioprotective and voluntary exercise performance eff ects after idebenone treatment. 13 The fi ndings from a phase 2 randomised placebo-controlled trial (DELPHI) showed benefi cial eff ects of idebenone on early functional cardiac and respiratory markers. 14 An important fi nding from the DELPHI study was that patients treated with idebenone had stabilised peak expiratory fl ow as percentage predicted (PEF%p), a marker of expiratory muscle strength compared with a reduction in patients given placebo. Additional analyses indicated that the eff ect of idebenone on respiratory function outcomes was larger in patients not taking concomitant glucocorticoids. 15 We investigated the effi cacy, tolerability, and safety of idebenone in a confi rmatory phase 3 trial in patients with Duchenne muscular dystrophy not taking concomitant glucocorticoids.
Methods

Study design and patients
Patients aged 10-18 years with a documented diagnosis of Duchenne muscular dystrophy were eligible for inclusion in this phase 3 trial. Recruiting centres were in Belgium, Germany, the Netherlands, Switzerland, France, Sweden, Austria, Italy, Spain, and the USA. A full list of inclusion, exclusion, and withdrawal criteria is provided in the appendix.
Patients were enrolled between July 27, 2009 (study start date), and Dec 14, 2012 ; the study end date (last patient completed the study) was Jan 14, 2014.
Randomisation and masking
We used an interactive web response system to randomly allocate patients in a one-to-one ratio with a permuted block design with four patients per block to fi lm-coated tablets of idebenone (150 mg per tablet, Raxone/Catena, Santhera Pharmaceuticals, Liestal, Switzerland; 300 mg three times a day, orally, during meals) or matching placebo for 52 weeks. Two siblings of patients who were already randomly allocated were assigned to the same group as their siblings to avoid mix up of study medication. Randomisation was balanced for PEF%p at baseline (two PEF%p strata: <40%p and 40-80%p). All study personnel and patients were masked to treatment group assignment. Compliance was monitored with entries in a patient's diary and pill counts. After enrolment, safety and effi cacy were assessed during hospital visits at weeks 13, 26, 39, and 52. Additional safety assessments were undertaken 4 weeks after randomisation and at the follow-up visit 4 weeks after the week 52 visit or after early discontinuation of study medication. Patients were instructed and educated to assess their weekly respiratory function (peak expiratory fl ow [PEF] and forced expiratory volume in 1 s [FEV 1 ]) using the hand-held ASMA-1 device (usb model 4000, Vitalograph, Maids Moreton, UK) at home. The study had several protocol amendments, which are listed in the appendix.
The trial and any changes to the protocol were approved by relevant national authorities and the institutional review boards or independent ethics committees in the countries of the participating centres and done in accordance with good clinical practice and the principles of the Declaration of Helsinki. We obtained written informed consent from patients.
Outcomes
The primary objective was to assess the effi cacy of idebenone, compared with placebo, in improving or reducing loss of respiratory function, measured by a qualifi ed, trained, and certifi ed evaluator at each centre in accordance with standardised procedures and international guidelines. Pulmonary function tests were done at each hospital visit with a Pneumotrac Spirometer 6800 (Vitalograph) and maximal static airway pressures were assessed with a MicroRPM instrument (Medical Supply Store, Chorley, UK). At each hospital visit, PEF and FEV 1 were also measured with the patient's portable See Online for appendix Figure 1 : Trial profi le PEF%p=peak expiratory fl ow as percentage predicted. ITT=intention to treat. mITT=modifi ed intention to treat. *Two patients were unable to form a mouth seal, two had PEF %p greater than 80% at baseline, two required assisted ventilation, one patient was using steroids, one required spinal fi xation surgery, two patients were unable to comply with study procedures, one patient withdrew informed consent, one was a smoker, and four patients had one or more other reasons for exclusion. 
Statistical analysis
A statistical analysis plan was prepared before the database was locked. The primary analysis of the primary endpoint (change in PEF%p from baseline to week 52) was to be made in a modifi ed intention-to-treat population (mITT; appendix), which excluded patients with at least 20% diff erence in the yearly change in PEF%p measured with hospital-based spirometry and home-based ASMA-1 assessments. Like all the other endpoints, the primary endpoint was also calculated in the full ITT population. Continuous variables were analysed with a mixed model for repeated measurements with treatment group, visit, and interaction between treatment group and visit used as fi xed factors in the model and baseline assessment used as a covariate. For responder analyses, responders were defi ned as patients who did not have deterioration in respiratory function tests. Responder rates were compared between treatment groups with the Cochran-MantelHaenszel test with missing data imputed with the last observation carried forward method. All hypotheses tested and 95% CIs presented were two-sided and p values of less than 5% were signifi cant without adjustment for multiplicity and regarded as exploratory except for the primary endpoint. The sample size for the study provided 80% power to detect a diff erence of 10•3% in PEF%p. A planned futility analysis was done after all 64 patients had been randomly assigned and 37 had completed the trial. This analysis, done by the data and safety monitoring board, confi rmed non-futility of the trial. This study is registered with ClinicalTrials.gov, number NCT01027884.
Role of the funding source
The study funder was involved in the study design, and data gathering and analysis. The investigators and all authors had sole discretion in the data analysis and interpretation, writing of the report, and the decision to submit for publication.
Results
96 patients were screened and 29 were excluded from participation because they did not meet inclusion or exclusion criteria. 65 patients were randomly assigned and two patients were allocated to the same treatment as their randomly assigned siblings (fi gure 1). One patient never took study medication, resulting in 66 patients who were treated and included in the safety population (34 in the placebo group and 32 in the idebenone group). 55 patients completed the trial and 11 withdrew or Baseline respiratory function test Patients were well balanced between treatment groups for baseline respiratory function variables (table 1) . The primary effi cacy variable (PEF%p), as measured with hospital-based spirometry or with the home-based ASMA-1 device, was similar between groups at baseline (appendix), confi rming the reliability of the data obtained.
For the primary endpoint (mITT population), there was a signifi cant fall in PEF%p by 9·01%p (95% CI -13·18 to -4·84; p=0·0001) from baseline to week 52 in the placebo group compared with a non-signifi cant decline of 3·05%p (-7·08 to 0·97; p=0·134) in the idebenone group, resulting in a signifi cant diff erence between treatment groups of 5·96%p (0·16 to 11·76; p=0·044) at week 52 and this represented a 66% reduction in loss of PEF%p. The eff ect of idebenone was signifi cant at week 26 (p=0·007) and week 39 (p=0·034) and at all post-baseline assessment timepoints together (p=0·018). Baseline PEF%p values in the mITT population were well balanced (idebenone 53·1%p [SD 10·2] and placebo 54·3%p [13·5]). Similar results were obtained for the full ITT population with a signifi cant decline in PEF%p from baseline to week 52 in the placebo group by 8·84%p (95% CI -12·73 to -4·95; p<0·0001) compared with a non-signifi cant decline of 2·57%p (-6·68 to 1·54; p=0·215) in the idebenone group, resulting in signifi cant diff erences between treatment groups at week 52 (6·27%p [0·61 to 11·93]; p=0·031) and at other study timepoints (fi gure 2A; endpoints, measured at home with the ASMA-1 device, through linear regression analysis for the yearly change (p=0·055) and mean of data obtained during 6 weeks around hospital visits (p=0·028; fi gure 3; appendix). Sensitivity analyses were done to assess the robustness of the results by applying diff erent imputation methods for missing data in the ITT population, analysing a diff erent population, and by excluding patients likely to aff ect the results (fi gure 3). The results show that the treatment eff ect was not altered by diff erent assumptions about missing data or by the exclusion of data for patients defi ned as being in diff erent populations. Diverging trajectories between treatment groups were also noted in PEF with signifi cant diff erences between treatment groups at week 52 (28·1 L/min [95% CI 2·69 to 53·50]; p=0·031) and at other visit timepoints (fi gure 2B; table 2; appendix). Other respiratory function endpoints such as FVC%p, FVC, FEV 1 %p, and FEV 1 showed a consistent pattern with treatment diff erences, lending support to the effi cacy of idebenone over placebo in the preservation of respiratory function (fi gure 2C-F; appendix). Change from baseline to week 52 was well correlated between PEF%p and FVC%p (r²=0·333; p<0·0001; appendix). No signifi cant diff erences were noted in the change from baseline to week 52 for MIP, MEP, and peak cough fl ow (data not shown). Also, no treatment eff ect was noted in upper limb strength (measured with hand-held myometry) and function (assessed with the Brooke's scale) and patient-reported outcomes assessed with Pediatric Quality of Life Inventory (data not shown).
Since the study population was a mix of patients who in the past had used glucocorticoids and patients who had never used steroids (table 1), it was of interest to assess whether previous steroid use aff ected the outcome of respiratory function tests. Post-hoc analysis showed that respiratory function test outcomes were similar between patients with previous steroid use and steroid-naive patients (appendix). To investigate the eff ect of age, dichotomised age at baseline (≤14 years or >14 years) and the interaction between age and treatment group were included as fi xed factors in the model in a post-hoc analysis. Both these factors were nonsignifi cant for PEF%p (p=0·384 and p=0·819) and FVC%p (p=0·141 and p=0·941), showing that age did not aff ect the outcome for PEF%p and FVC%p. Treatment eff ects were also assessed for the ITT patient subgroups separated by the median age (14 years). A positive treatment eff ect in favour of idebenone was evident from this post-hoc analysis for patients younger and older than 14 years of age (appendix).
Positive outcomes favouring idebenone over placebo were further supported by the results of prespecifi ed responder analyses, which showed a higher proportion of idebenone-treated patients who did not deteriorate in respiratory function tests between baseline and week 52 (table 3) .
Idebenone's eff ects were also supported with clinical fi ndings. In a prespecifi ed analysis, we counted the number of patients who at any time during the trial dropped below 160 L/min in peak cough fl ow, a clinically meaningful threshold below which cough is no longer eff ective enough to provide adequate mucociliary clearance and consensus care recommends mechanical cough assistance. 7, 22, 23 In the ITT population there were six (18%) of 33 patients in the placebo group but only one (4%) of 25 patients in the idebenone group above the threshold at baseline falling below the 160 L/min threshold. Moreover, the results of a post-hoc analysis showed that there were fi ve (16%) of 32 patients in the placebo group but only one (3%) of 31 patients in the idebenone group who fell below 1 L in FVC, a clinically important threshold and predictor of early mortality. 24 Also, the number of patients reporting upper respiratory tract infection-related adverse events was lower in the idebenone group than in the placebo group (appendix). Similarly, there were more patients in the placebo group reporting lower respiratory tract infection-related adverse events (bronchitis and pneumonia) than in the idebenone group, although the diff erence was not signifi cant (appendix).
Treatment with idebenone was safe and well tolerated. No deaths occurred during the study. Of the 66 patients included in the safety analyses, 62 (94%) had at least one adverse event: 30 (94%) in the idebenone group and 32 (94%) in the placebo group. Nasopharyngitis (26%) and headache (20%) were the most common adverse events without diff erences in their incidence between the treatment groups (appendix). Transient and mild diarrhoea, a known side-eff ect of idebenone intake, was more common in idebenone-treated patients (25% vs 12%), whereas constipation was more common in the placebo group than in the idebenone group (18% vs 9%; appendix). Most adverse events were of mild or moderate intensity. Serious adverse events were reported in 6% and severe adverse events in 3% of idebenone-treated patients and in 15% and 12% of placebo-treated patients, none of which were classifi ed as related to intake of study medication (appendix). The adverse events that led to discontinuation of treatment were sleep apnoea syndrome (n=1) and diarrhoea (n=1) in the idebenone group and supraventricular arrhythmia and respiratory failure with pneumonia in the placebo group (all in same patient). None of the adverse events that led to premature discontinuation from the study were judged by the investigator to be related to study treatment. There was no evidence for a clinically relevant eff ect of idebenone on any haematological or clinical chemistry variable, vital signs, physical examinations, or results from ECG and echocardiography assessments.
Discussion
The DELOS trial met its primary objective and the results showed that idebenone signifi cantly reduced the loss of respiratory function in patients with Duchenne muscular dystrophy.
Ventilatory support and the chronic use of glucocorticoids have contributed to increased longevity in patients with Duchenne muscular dystrophy. Nevertheless, respiratory complications continue to be a main cause of early morbidity and mortality in steroidtreated patients and a subset of patients with Duchenne muscular dystrophy do not respond to or do not tolerate steroid treatment. In an attempt to develop novel treatment options, and continuing from previous studies, 13, 14 we have now investigated the effi cacy and safety of idebenone in patients with Duchenne muscular dystrophy in the fi rst ever successful phase 3 study of patients with this disease (panel).
Based on the results from a phase 2 study, 14 PEF was selected as the primary effi cacy variable, which in the absence of bronchial obstruction is a measure of expiratory muscle strength. In patients with Duchenne muscular dystrophy, progressive weakness of chest wall muscles precedes weakness of the diaphragm (used mainly for inspiratory function) and leads to restrictive lung volume changes (ie, reduced FVC). 4, [25] [26] [27] [28] Compared with other respiratory variables, FVC is less sensitive to mild muscle weakness in the early stages of the disease.
9,29 Loss of lung volume initially results from the inability to pull up the respiratory system to total lung capacity and to push it down to residual volume. In the later stage of disease, additional restriction occurs as a result of progressive muscle fi brosis and changes in lung and chest wall recoil. Therefore, respiratory strength might be more sensitive to treatment intervention than is lung volume, because this is aff ected not only by respiratory muscle strength but also by thoracic wall compliance and deformities. Additionally, abnormal respiratory mech anics in Duchenne muscular dystrophy are not restricted to the lungs and chest wall and might also involve the upper airways. 30 Here, weakness of pharyngeal dilator muscles decreases upper airway calibre, causing an increase in upper airway resistance during inspiration, which imposes an increased mechanical load on the diaphragm and other inspiratory muscles. 31 Therefore, PEF is a measure not only of expiratory strength but also inspiratory eff ort and upper airway resistance. 32, 33 In the DELOS trial, there was a signifi cant fall in PEF%p from baseline to week 52 in the placebo group compared with a non-signifi cant decline in the idebenone group, resulting in a signifi cant and clinically relevant idebenone treatment eff ect. No treatment eff ect was noted for MIP and MEP, which at baseline were more severely aff ected than were the expiratory fl ow and lung volume variables. These low baseline values are in line with previous data indicating that maximum static airway
Panel: Research in context
Systematic review
We searched PubMed and clinical trial registries for registrations and reports of randomised double-blind placebo-controlled trials of idebenone in the treatment of patients with Duchenne muscular dystrophy. We identifi ed only one study (phase 2 DELPHI trial; ClinicalTrials.gov, number NCT00654784). The phase 3 DELOS trial of idebenone in patients with dystrophin-defi cient muscular dystrophy was based on existing evidence: an observer-masked long-term placebo-controlled study in the mdx mouse model of Duchenne muscular dystrophy and the proof-of-concept phase 2 DELPHI trial in patients with Duchenne muscular dystrophy. The results of the animal model study showed phenotypic correction with substantial cardioprotection and voluntary exercise performance improvement. DELPHI's results showed a signifi cant respiratory eff ect of idebenone on peak expiratory fl ow (primary endpoint in DELOS). The design of the DELOS trial was based on the DELPHI fi ndings and scientifi c advice consultation with regulatory authorities. The DELPHI and DELOS trials had some diff erences in drug dosing and patients' characteristics. In DELPHI, idebenone was dosed at 450 mg daily (because of few safety data available at the time); in DELOS we used 900 mg daily. Patients in DELPHI were aged 8-16 years and were a mix of individuals not using concomitant glucocorticoids and those on steroids for Duchenne muscular dystrophy. The DELOS study population consisted of 10-18-year-old patients not taking concomitant glucocorticoids.
Interpretation
To the best of our knowledge, we report for the fi rst time a phase 3 randomised controlled trial in patients with Duchenne muscular dystrophy with a positive outcome. Signifi cant and clinically relevant results for primary and secondary endpoints showed that idebenone reduced the loss of respiratory function in 10-18-year-old patients with Duchenne muscular dystrophy who were not using concomitant glucocorticoids. Also, idebenone was safe and well tolerated. The relevance of modifying the natural course of respiratory disease in Duchenne muscular dystrophy is emphasised in clinical practice where respiratory failure leads to ventilator-dependency and continues to be the predominant cause of early death in patients with Duchenne muscular dystrophy.
pressures are regarded as early markers of respiratory dysfunction in Duchenne muscular dystrophy and their much reduced values at study start could have precluded the detection of any treatment eff ect.
Morbidity and mortality in patients with Duchenne muscular dystrophy are associated with progressive restrictive lung disease and irreversible loss of lung function, commonly measured as a reduction in FVC. 24 Therefore, reducing the decline in FVC, as shown in this trial, is of clinical relevance. In DELOS, the decrease in FVC in the placebo group is similar to recent natural history data in steroid-naive patients with Duchenne muscular dystrophy. 24, 34 Furthermore, the idebenone eff ect size in DELOS is similar to outcomes reported for investigational treatments of idiopathic pulmonary fi brosis, another restrictive lung disease (appendix). 35, 36 Results from a phase 2 trial (DELPHI) showed a larger eff ect size of idebenone on respiratory function in patients not taking concomitant glucocorticoids than in patients who took steroids. 15 To account for this infl uence, only patients not using concomitant steroids were enrolled in DELOS. Subgroup analyses showed that the eff ect sizes in favour of idebenone for PEF, FVC, and FEV 1 were generally similar between patients who were steroid naive and those who had used steroids in the past for Duchenne muscular dystrophy. These results are in agreement with previous fi ndings that lung volume measurements in past users of steroids are not diff erent from steroid-naive patients, 9 indicating that the thera peutic eff ect of steroids on respiratory function is diminished after their discontinuation. Although data from the current trial were obtained in patients not using steroids, there is no reason a priori why idebenone could not also be exerting a treatment eff ect in patients using steroids concomitantly. However, it might be challenging to convincingly show this additive eff ect of idebenone on top of steroids. 15 The results of DELOS showed a somewhat larger eff ect size for PEF%p and FVC%p in the subgroup of patients aged 14 years and younger than in the older patients (appendix), indicating that patients may derive a larger benefi t from idebenone if treatment is initiated early.
Idebenone was safe and well tolerated with frequency and severity of adverse events that were similar between treatment groups, in line with previous reports. 14, 37 Limitations of this study are related to the sample size and treatment duration. The study had several protocol amendments (appendix), most notably an amendment that defi ned the fi nal study population to the subgroup of patients not using glucocorticoids. No patients using concomitant glucocorticoids were enrolled in the study. The robustness of the outcome was assessed with sensitivity analyses by use of diff erent imputation methods, by excluding patients whose inclusion might aff ect the outcome, and with diff erent assessment methods and intervals. Overall, the data set is robust, thereby alleviating concerns that might result from the small sample size of the study. The duration of a placebo-controlled trial in children with Duchenne muscular dystrophy with advanced disease inevitably has to be limited by ethical reasons. Although a study of 12 months cannot provide data on hard outcome measures such as time to assisted ventilation or death, this limitation is mitigated by the consistency of the idebenone eff ects on respiratory function outcomes (PEF, FVC, and FEV 1 ) together with clinically relevant fi ndings. Specifi cally, the proportion of patients with reductions in FVC or peak cough fl ow below crucial thresholds, [22] [23] [24] 38 known to be predictive of imminent ventilatory failure, and the reduced number of upper airway tract infections in the idebenone group, are strongly supportive for the clinical meaningfulness of the idebenone eff ect. The overall number of lower airway tract infections reported during the 1-year follow-up was small and, therefore, no conclusion can be drawn. However, the numerical diff erence in favour of idebenone treatment is encouraging and merits further investigation during longer follow-up.
In the past, improved patient care with best-practice recommendations and the introduction of glucocorticoids has greatly increased the survival time of patients with Duchenne muscular dystrophy. 7, 8, 39, 40 Nevertheless, loss of respiratory function continues to be a predominant cause of early morbidity and mortality in patients with Duchenne muscular dystrophy. Effi cacy data from this trial show that idebenone signifi cantly reduced the loss of respiratory function in patients with Duchenne muscular dystrophy who were not taking concomitant glucocorticoids. With its favourable safety and tolerability profi les, idebenone therefore is a suitable treatment option to ameliorate a life-threatening complication of Duchenne muscular dystrophy.
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